6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04976127 (ClinicalTrials.gov) | December 7, 2021 | 16/5/2021 | Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients | Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients | Parkinson Disease | Drug: Talineuren | InnoMedica Schweiz AG | NULL | Recruiting | 40 Years | 80 Years | All | 12 | Phase 1 | Switzerland |